Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 180

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 180
---
 €0.1 million in 2024, €0.4 million in 2023 and €3.8 million in 2022 to expand our overall lab testing capacity;
----------------------------------------------------------------------------------------------------------------------------------

●   investments for a new data center building in Los Angeles to support all IT services and to address current risks with the existing data center of €0.1 million in 2024, €0.2 million in 2023 and €0.9 million in 2022;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investment of €3.8 million in 2022 for the acquisition of a new property of 79,180 square meters adjacent to our Barcelona manufacturing facilities to expand our industrial and research capabilities, adding to our current workforce in the region by more than 3,500 employees;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments to update manufacturing facilities to EMA regulation related to the manufacturing of sterile medicinal products of €1.6 million in 2024, €2.3 million in 2023 and €5.1 million in 2022;
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments to increase our IVIG purification capacity of €2.2 million in 2024, €1.0 million in 2023 and €0.8 million in 2022; and
--------------------------------------------------------------------------------------------------------------------------------------

●   investment of €4.0 million in 2024, €4.5 million in 2023 and €9.7 million in 2022, related with IT projects for plasma collection centers.
----------------------------------------------------------------------------------------------------------------------------------------------
January 2025 through December 2026
In 2024, we completed a €1.9 billion investment plan initiated in 2018 that involved, among other investments, cumulative industrial capital investments to expand the manufacturing capacities of the Biopharma business unit, as well as investments in the Diagnostic business unit. We are currently focusing our capital expenditures on the maintenance of our facilities while we formulate a large-scale strategy for 2025 and 2026.
The majority of our capital investments benefit our Biopharma business unit, systemically enhancing our manufacturing facilities. We aim to optimize utilization of our fractionation capacity by obtaining FDA and EMA licenses and completing other requirements to purify any of our intermediate products at any of our plants. We are also relocating and renovating plasma donation centers and improving infrastructures related to raw materials classification, preparation and storage facilities, logistics centers and analysis laboratories.
The most important planned capital projects relating to the improvement of our manufacturing facilities are:

●   Montreal: